Literature DB >> 19543297

Marine-derived oligosaccharide sulfate (JG3) suppresses heparanase-driven cell adhesion events in heparanase over-expressing CHO-K1 cells.

Qiu-Ning Li1, Hai-Ying Liu, Xian-Liang Xin, Qiu-Ming Pan, Lu Wang, Jing Zhang, Qin Chen, Mei-Yu Geng, Jian Ding.   

Abstract

AIM: To elucidate the detailed mechanisms underlying the appreciable effects of JG3, a novel marine-derived oligosaccharide, on cell migration using a Chinese hamster ovary (CHO) cell line stably over-expressing heparanase.
METHODS: A retrovirus infection system was used to establish a CHO-K1 cell line stably transfected with heparanase. Immunocytochemistry was used to assess cell morphology. Flow cytometry was selected to analyze the activation of beta1-integrin, and Western blotting was used to analyze the downstream effects on the cell adhesion pathway. An affinity precipitation assay was used to determine activation of the small GTPases, Rac1, and RhoA.
RESULTS: JG3 abolished heparanase-driven formation of focal adhesions and cell spreading. Although JG3 failed to block the heparanase-triggered activation of beta1-integrin or the phosphorylation of Src, the oligosaccharide caused a significant dephosphorylation of FAK and subsequent inactivation of Erk. Furthermore, JG3 was found to arrest the activation of Rac1.
CONCLUSION: All these findings help form an alternative view to understand the mechanisms underlying the inhibitory effects of JG3 on cell motility.Acta Pharmacologica Sinica (2009) 30: 1033-1038; doi: 10.1038/aps.2009.97; published online 22 June 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543297      PMCID: PMC4006649          DOI: 10.1038/aps.2009.97

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  24 in total

Review 1.  Integrins in invasive growth.

Authors:  Cord Brakebusch; Daniel Bouvard; Fabio Stanchi; Takao Sakai; Reinhard Fässler
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Heparanase mediates cell adhesion independent of its enzymatic activity.

Authors:  Orit Goldshmidt; Eyal Zcharia; Miriam Cohen; Helena Aingorn; Irit Cohen; Liat Nadav; Ben-Zion Katz; Benjamin Geiger; Israel Vlodavsky
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

Review 3.  Rho and Rac take center stage.

Authors:  Keith Burridge; Krister Wennerberg
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 4.  Integrin signaling: it's where the action is.

Authors:  Caroline H Damsky; Dusko Ilić
Journal:  Curr Opin Cell Biol       Date:  2002-10       Impact factor: 8.382

5.  Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts.

Authors:  Ilya Sotnikov; Rami Hershkoviz; Valentin Grabovsky; Neta Ilan; Liora Cahalon; Israel Vlodavsky; Ronen Alon; Ofer Lider
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

Review 6.  Anchorage-dependent ERK signaling--mechanisms and consequences.

Authors:  Alan K Howe; Andrew E Aplin; R L Juliano
Journal:  Curr Opin Genet Dev       Date:  2002-02       Impact factor: 5.578

7.  Heparanase affects adhesive and tumorigenic potential of human glioma cells.

Authors:  Anna Zetser; Yulia Bashenko; Hua-Quan Miao; Israel Vlodavsky; Neta Ilan
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

8.  Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines.

Authors:  M Nakajima; T Irimura; D Di Ferrante; N Di Ferrante; G L Nicolson
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

9.  A novel RGD-independent fibronectin assembly pathway initiated by alpha4beta1 integrin binding to the alternatively spliced V region.

Authors:  J L Sechler; A M Cumiskey; D M Gazzola; J E Schwarzbauer
Journal:  J Cell Sci       Date:  2000-04       Impact factor: 5.285

10.  Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans.

Authors:  Flonia Levy-Adam; Sari Feld; Edith Suss-Toby; Israel Vlodavsky; Neta Ilan
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

View more
  7 in total

1.  Oligomannurarate sulfate blocks tumor growth by inhibiting NF-kappaB activation.

Authors:  Jing Zhang; Yi Chen; Xian-liang Xin; Qiu-ning Li; Ming Li; Li-ping Lin; Mei-yu Geng; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2010-02-15       Impact factor: 6.150

Review 2.  Newly discovered angiogenesis inhibitors and their mechanisms of action.

Authors:  Ze-hong Miao; Jian-ming Feng; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

3.  Oligomannurarate sulfate inhibits CXCL12/SDF-1-mediated proliferation and invasion of human tumor cells in vitro.

Authors:  Wei-wei Wen; Shao Xie; Xian-liang Xin; Mei-yu Geng; Jian Ding; Yi Chen
Journal:  Acta Pharmacol Sin       Date:  2013-10-21       Impact factor: 6.150

4.  CTC clusters induced by heparanase enhance breast cancer metastasis.

Authors:  Rong-Rui Wei; Dan-Ni Sun; Hong Yang; Juan Yan; Xiong Zhang; Xing-Ling Zheng; Xu-Hong Fu; Mei-Yu Geng; Xun Huang; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2018-02-08       Impact factor: 6.150

5.  Heparanase Loosens E-Cadherin-Mediated Cell-Cell Contact via Activation of Src.

Authors:  Victoria Cohen-Kaplan; Neta Ilan; Israel Vlodavsky
Journal:  Front Oncol       Date:  2020-01-22       Impact factor: 6.244

6.  PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.

Authors:  Edward Hammond; Ralf Brandt; Keith Dredge
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 7.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.